Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
4 studies found for:    20728210 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Phase II Study of Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer
Conditions: Stomach Neoplasms;   Neoplasms Metastasis;   ERBB2 Gene Amplification
Interventions: Drug: Trastuzumab;   Drug: Docetaxel;   Drug: Capecitabine
2 Active, not recruiting Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC)
Conditions: Metastatic or Recurrent Gastric Adenocarcinoma;   Her-2 Positive Gastric Cancer
Intervention: Drug: Herceptin+XELOX
3 Recruiting T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy
Condition: Gastric Cancer
Interventions: Drug: Trastuzumab;   Drug: Capecitabine;   Drug: Oxaliplatin
4 Completed
Has Results
ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: Trastuzumab;   Drug: Fluorouracil;   Drug: Cisplatin;   Drug: Capecitabine

Indicates status has not been verified in more than two years